EJC paediatric oncology最新文献

{"title":"Corrigendum to “European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence” [EJC Paediatr. Oncol. 5 (2025) 100227]","authors":"Alba Rubio-San-Simón , Timothy A. Ritzmann , Denise Obrecht-Sturm , Martin Benesch , Beate Timmermann , Pierre Leblond , John-Paul Kilday , Geraldina Poggi , Nicola Thorp , Maura Massimino , Marie-Lise van Veelen , Martin Schuhmann , Ulrich-Wilhelm Thomale , Stephan Tippelt , Ulrich Schüller , Stefan Rutkowski , Richard G. Grundy , Stephanie Bolle , Ana Fernández-Teijeiro , Kristian W. Pajtler","doi":"10.1016/j.ejcped.2025.100305","DOIUrl":"10.1016/j.ejcped.2025.100305","url":null,"abstract":"","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"6 ","pages":"Article 100305"},"PeriodicalIF":0.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144580183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trial","authors":"Michael Karremann ,&nbsp;Thomas Perwein ,&nbsp;André O. von Bueren ,&nbsp;Gerrit H. Gielen ,&nbsp;Martin Benesch ,&nbsp;Gunther Nussbaumer ,&nbsp;Lea L. Friker ,&nbsp;Andreas Waha ,&nbsp;Dominik Sturm ,&nbsp;David T.W. Jones ,&nbsp;Olaf Witt ,&nbsp;Stefan M. Pfister ,&nbsp;Matthias Eyrich ,&nbsp;Ulrich W. Thomale ,&nbsp;Chiara Valentini ,&nbsp;Mechthild Krause ,&nbsp;Stefaan W. Van Gool ,&nbsp;Michael C. Frühwald ,&nbsp;Pablo Hernaiz-Driever ,&nbsp;Martin Ebinger ,&nbsp;Christof M. Kramm","doi":"10.1016/j.ejcped.2025.100308","DOIUrl":"10.1016/j.ejcped.2025.100308","url":null,"abstract":"<div><h3>Background</h3><div>The HIT-HGG-2007 trial investigated temozolomide (TMZ) radio-chemotherapy for pediatric patients with high-grade gliomas (pHGG) to demonstrate therapeutic non-inferiority compared to previous intensive radio-chemotherapy regimens (HIT-GBM-C/-D).</div></div><div><h3>Methods</h3><div>Between June 2009 and December 2016, 456 patients were enrolled into this international, prospective, single-arm, multicenter phase II trial in Germany, Austria, and Switzerland of whom 438 patients were evaluable for confirmatory analysis. Patients from the HIT-GBM-C/-D trials served as historic control (n = 439). Tumors of both cohorts with available tissue were re-classified according to the 2021 WHO classification of CNS tumors (n = 140).</div></div><div><h3>Results</h3><div>Regarding event-free-survival (EFS) rate at 6 months, non-inferiority of the HIT-HGG-2007 regimen was confirmed (p = 0.0125). In terms of exploratory analyses, median EFS and overall survival (OS) was 9.5 months (95 % confidence interval [CI95], 8.9–10.4) and 14.7 months (CI95, 13.5–16.3), superior to intensive chemotherapy regimens (p &lt; 0.0001 and p = 0.0328). EFS and OS remained superior after re-classification of tumors according to WHO2021 criteria. TMZ radio-chemotherapy had lower rates of severe hematological, gastrointestinal, and hepatic toxicity compared to HIT-GBM-C/-D. Younger age, WHO grade IV histology, tumor location in the brainstem or basal ganglia, and lower extent of resection were independent adverse risk factors for OS and EFS. <em>MGMT</em> gene promoter methylation status had no impact on EFS and OS.</div></div><div><h3>Conclusions</h3><div>The HIT-HGG-2007 trial demonstrated non-inferiority compared with intensive chemotherapy regimens. <em>MGMT</em> promotor methylation status had no impact on survival. Exploratory analysis supports treatment of newly diagnosed non-pontine pHGG according to the HIT-HGG-2007 regimen due to improved EFS and OS rates together with a favorable toxicity profile.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"6 ","pages":"Article 100308"},"PeriodicalIF":0.0,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144587417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hearing your child is diagnosed with leukemia: A qualitative study into parents’ perspectives","authors":"Petra Buursma ,&nbsp;Daniël Zwerus ,&nbsp;Esther M.M. van den Bergh ,&nbsp;Natasja Dors ,&nbsp;Peter M. Hoogerbrugge ,&nbsp;Martha A. Grootenhuis ,&nbsp;Marijke C. Kars ,&nbsp;Sasja A. Schepers","doi":"10.1016/j.ejcped.2025.100307","DOIUrl":"10.1016/j.ejcped.2025.100307","url":null,"abstract":"<div><h3>Introduction</h3><div>Hearing a pediatric leukemia diagnosis is overwhelming. Parent satisfaction with the diagnostic conversation contributes to building trust in the oncologist and adaptation to the disease. Limited research has explored parental communication needs during this critical moment. This study aimed to explore parental experiences with communication during diagnostic conversations in pediatric leukemia.</div></div><div><h3>Methods</h3><div>In this qualitative study, we conducted a thematic analysis on semi-structured interviews with parents of children diagnosed with leukemia between June 2022 and February 2023.</div></div><div><h3>Results</h3><div>In total, 25 interviews were conducted with 30 parents (47 % male) of 19 children. Parents described entering the diagnostic conversation in emotional shock, while simultaneously trying to regain control to fulfill their new parental role. We identified three themes facilitating this process. First, parents felt supported by (1) the freedom to ask questions and (2) appropriate responses to their emotions when they were expressed. Nevertheless, if they did not express their emotions, they preferred not being asked about them explicitly. Second, parents appreciated practical information to organize and maximize chances of survival, but felt additional burden when the child was overlooked during the conversation. Third, parents established trust in the oncologist based on their expertise, calm attitude and appearance of mutual respect. Parents valued decisions being made for them, if oncologists were transparent about their reasoning.</div></div><div><h3>Conclusion</h3><div>Results show the importance of validating parents’ preferences during the diagnostic conversation (e.g. about including the child and decision-making). Communication training may support oncologists in understanding the importance of exploring parental communication preferences during diagnostic conversations.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"6 ","pages":"Article 100307"},"PeriodicalIF":0.0,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144587418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HOW ARE YOU FEELING TODAY? – Gaps and opportunities in capturing patient reported outcomes (PROs) in Pediatric Cancer Care","authors":"Anna Zettl ,&nbsp;Hannah Gsell ,&nbsp;Karolina Maślak ,&nbsp;Antti Karjalainen ,&nbsp;Ulrike Leiss ,&nbsp;Anita Kienesberger ,&nbsp;Carina Schneider","doi":"10.1016/j.ejcped.2025.100306","DOIUrl":"10.1016/j.ejcped.2025.100306","url":null,"abstract":"<div><div>Including children's perspectives in healthcare and clinical trials, particularly in pediatric oncology, is critical to promoting child-centered care. Research has shown that even very young children can understand complex medical concepts, highlighting the psychological and practical benefits of involving children in their care. Patient-Reported Outcome Measures (PROMs) play a critical role in capturing young patients' insights about their symptoms and well-being. This enables individualized care and an improvement in quality of life. Despite their potential, the use of PROMs in pediatric oncology faces significant challenges, including age-related barriers to understanding and the exclusion of cognitively impaired children. PROMs, when used effectively, can empower patients, improve communication and influence clinical decisions in favor of young patients. However, their relevance depends on the active participation of patients and caregivers in their design and use. PROMs also need to be further developed in the area of survivorship to close gaps in long-term care where many physical and psychological problems otherwise go unrecognized. Tailoring PROMs to patients' needs ensures that every patient, regardless of age or neurocognitive ability, contributes to a comprehensive understanding of the impact of treatment. Incorporating PROMs into routine care and clinical trials, supported by patient advocacy and systematic implementation, can address critical gaps. This approach ensures that pediatric oncology adapts to the diverse needs of children and survivors to improve long-term outcomes and promote a truly patient-centered model.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"6 ","pages":"Article 100306"},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144653147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents","authors":"Sarah K. Tasian ,&nbsp;Judith M. Boer ,&nbsp;Monique L. den Boer","doi":"10.1016/j.ejcped.2025.100304","DOIUrl":"10.1016/j.ejcped.2025.100304","url":null,"abstract":"<div><div>This review aims to discuss similarities and dissimilarities between <em>BCR</em>::<em>ABL1</em>-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven <em>BCR::ABL1</em>-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with <em>BCR</em>::<em>ABL1</em>-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"6 ","pages":"Article 100304"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Tumor Lysis Syndrome in a pediatric patient with a reported higher serum uric acid level","authors":"Leisiane Bittencourt,&nbsp;Patrícia Martins,&nbsp;Ariadne Becker,&nbsp;Zeni Klem,&nbsp;Emannuely Izidoro","doi":"10.1016/j.ejcped.2025.100257","DOIUrl":"10.1016/j.ejcped.2025.100257","url":null,"abstract":"","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100257"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144756838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical complications and sociodemographic characteristics of pediatric patients with sickle cell anemia admitted to a Pediatric Intensive Care Unit in a level IV complexity hospital","authors":"Fernando Bermúdez Pupo ,&nbsp;María José Ruiz-Tello ,&nbsp;Ana María Bermúdez-Nessim ,&nbsp;Gustavo Andrés Duque ,&nbsp;Inés Elvira Gómez-Hernández ,&nbsp;María José Soto-Aparicio ,&nbsp;Jimena Sierra ,&nbsp;Sofía Martínez-Betancur ,&nbsp;Pamela Rodriguez ,&nbsp;Rubén Eduardo Lasso-Palomino","doi":"10.1016/j.ejcped.2025.100274","DOIUrl":"10.1016/j.ejcped.2025.100274","url":null,"abstract":"","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100274"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144756997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in deterioration events in a tertiary pediatric center in limited resource setting","authors":"Juliana Costa,&nbsp;Gladys Aceituno,&nbsp;Hilmarie Muniz-Talavera","doi":"10.1016/j.ejcped.2025.100264","DOIUrl":"10.1016/j.ejcped.2025.100264","url":null,"abstract":"","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100264"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality improvements in Barretos Cancer Hospital stimulated by the Critcom tool","authors":"Andreia Ribeiro Pereira Aguiar de Paula ,&nbsp;Gabriela Quevedo Garcia ,&nbsp;Regina Célia da Silva Dias ,&nbsp;Ana Carolina de Oliveira ,&nbsp;Ana Paula Rosa de Andrade ,&nbsp;Helena Andrade de Freitas ,&nbsp;Janaína Alves ,&nbsp;Mariana Ducatti Psy ,&nbsp;Eluiza Antonieta Moretto ,&nbsp;Angela Maria Puerto Torres ,&nbsp;Jocelyn Rivera","doi":"10.1016/j.ejcped.2025.100266","DOIUrl":"10.1016/j.ejcped.2025.100266","url":null,"abstract":"","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100266"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B","authors":"Lu Cao ,&nbsp;Shaoyan Hu ,&nbsp;Zhengjiang Bai ,&nbsp;Shuiyan Wu","doi":"10.1016/j.ejcped.2025.100300","DOIUrl":"10.1016/j.ejcped.2025.100300","url":null,"abstract":"","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100300"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144756957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}